Evolocumab

Cardiovascular Risk Reduction

Evolocumab is prescribed for adults with established heart or blood vessel disease. It is used to help lower the risk of the following events:

• Heart attack
• Stroke
• Coronary revascularization (procedures to restore blood flow to the heart)

High Cholesterol Treatment

This medication is used to treat primary hyperlipidemia, including a genetic condition called heterozygous familial hypercholesterolemia (HeFH). It is used alongside a low-fat diet and may be taken alone or with other cholesterol-lowering drugs, such as statins, to lower low-density lipoprotein (LDL) cholesterol.

Homozygous Familial Hypercholesterolemia

Evolocumab is also used to treat adults and children 10 years of age and older with homozygous familial hypercholesterolemia (HoFH). This is a rare, inherited condition that causes extremely high levels of LDL cholesterol. In these patients, the medication is typically used in combination with other lipid-lowering treatments.

The Role of LDL Receptors

The liver plays a key role in managing cholesterol levels. It uses specialized proteins on its surface called LDL receptors to capture "bad" cholesterol from the blood and bring it into the liver cells to be broken down and removed from the body.

How PCSK9 Affects Cholesterol

The body naturally produces a protein called proprotein convertase subtilisin/kexin type 9 (PCSK9). This protein binds to the LDL receptors on the liver and causes them to be destroyed. When there are fewer receptors available on the liver's surface, less cholesterol is removed from the blood, leading to higher levels of LDL cholesterol.

How Evolocumab Works

Evolocumab is a PCSK9 inhibitor. It works by attaching to the PCSK9 protein and preventing it from binding to the LDL receptors. This process leads to several effects:

• Increased Receptors: More LDL receptors remain active on the surface of the liver cells.
• Improved Clearance: The liver can more efficiently pull "bad" cholesterol out of the bloodstream.
• Lower Cholesterol Levels: As more cholesterol is removed and processed by the liver, the amount of LDL cholesterol circulating in the blood decreases significantly.

Because it works through this specific protein pathway, it is often used in combination with other cholesterol-lowering treatments, such as statins, to further reduce the risk of cardiovascular events.

Common Side Effects

Many people using this medication experience mild side effects that often do not require medical intervention. These may include:

• Redness, itching, swelling, bruising, or pain at the site of injection.
• Common cold symptoms, such as a runny nose, sore throat, or sneezing.
• Flu-like symptoms.
• Back pain.
• Muscle aches or joint pain.
• Cough.
• Dizziness.
• High blood sugar levels.

Serious Side Effects

While less common, some side effects can be serious. You should contact a healthcare provider immediately if you experience symptoms of a severe allergic reaction, which may include:

• Severe rash or hives.
• Intense itching.
• Swelling of the face, lips, tongue, or throat.
• Difficulty breathing or swallowing.
• Severe dizziness.

Hypersensitivity Reactions

Serious allergic reactions, including rash and hives, have been reported in individuals using evolocumab. If a serious hypersensitivity reaction occurs, the medication is typically discontinued and medical treatment is initiated.

Latex Sensitivity

The needle cover of the single-dose prefilled syringe and the single-dose prefilled autoinjector contains dry natural rubber, which is a derivative of latex. This may cause allergic reactions in people with a known sensitivity to latex. Individuals with latex allergies should discuss alternative delivery options with a healthcare provider.

Contraindications

Evolocumab is contraindicated in patients who have a history of a serious hypersensitivity reaction to evolocumab or any of the inactive ingredients in the product.

Pregnancy and Breastfeeding

There is limited information available regarding the safety of evolocumab use during pregnancy. It is also unknown whether the medication passes into human breast milk or if it could affect a nursing infant. Healthcare providers generally evaluate the risks and benefits before prescribing this medication to individuals who are pregnant or nursing.

Pediatric Use

The safety and effectiveness of evolocumab have been established for specific conditions in pediatric patients aged 10 years and older, such as homozygous familial hypercholesterolemia and heterozygous familial hypercholesterolemia. Its use in children younger than 10 years or for other conditions has not been established.

Pregnancy

There are no adequate and well-controlled studies of evolocumab use in pregnant women. As a monoclonal antibody, evolocumab is expected to be transported across the placenta as a pregnancy progresses, particularly during the second and third trimesters. This means the medication has the potential to be transmitted from the mother to the developing fetus.

In animal studies, no adverse effects on pregnancy or neonatal development were observed. However, because animal reproduction studies are not always predictive of human response, the use of this medication during pregnancy is generally only considered when the potential benefit justifies the potential risk to the fetus.

Breastfeeding

It is not known whether evolocumab is excreted in human milk. While many medications can pass into breast milk, it is currently unknown if evolocumab does so or if it could affect a nursing infant. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the medication to the mother.

Individuals who are pregnant, planning to become pregnant, or breastfeeding should discuss their treatment options and potential risks with their healthcare provider.

Available Forms

Evolocumab is a liquid solution administered by subcutaneous injection. It is available in the following single-use delivery systems:

• Prefilled Syringe: A manual injection device for single-use administration.
• Prefilled Autoinjector: A device that automates the injection process.
• On-body Infusor with Prefilled Cartridge: A wearable system that delivers the medication from a cartridge over a short period.

Each delivery format is intended for one-time use only and does not contain preservatives.

FDA Approval History

The U.S. Food and Drug Administration (FDA) first approved evolocumab in August 2015. It was the second medication in the PCSK9 inhibitor class to reach the market. Since its initial approval, the FDA has expanded its indications to include broader cardiovascular risk reduction and use in pediatric populations.

Approved Indications

Evolocumab is currently FDA-approved for the following uses:

• Cardiovascular Risk Reduction: To reduce the risk of heart attack, stroke, and coronary revascularization in adults with established cardiovascular disease.
• Primary Hyperlipidemia: To lower low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH).
• Homozygous Familial Hypercholesterolemia (HoFH): To lower LDL-C in adults and pediatric patients aged 10 years and older with this rare genetic condition.

Safety and Regulatory Status

There are currently no Boxed Warnings or Risk Evaluation and Mitigation Strategy (REMS) programs required by the FDA for evolocumab. The medication is available only by prescription and is intended for use in combination with a heart-healthy diet, either alone or alongside other cholesterol-lowering therapies like statins.

Regulatory approval was supported by clinical trials demonstrating that evolocumab significantly lowers LDL cholesterol levels and reduces the occurrence of major cardiovascular events in patients with high risk or established heart disease.

Insurance and Prior Authorization

Evolocumab is a specialty medication that often requires prior authorization from insurance providers. This process involves your healthcare provider submitting documentation to prove the medical necessity of the drug before the insurance company agrees to cover the cost.

Out-of-Pocket Expenses

The amount you pay out-of-pocket depends on your specific insurance plan's formulary, deductible, and copayment or coinsurance requirements. For those without insurance, the retail price of the medication is generally high, reflecting its status as a biologic therapy.

Financial Support Options

There are several resources that may help manage the cost of evolocumab:

• Manufacturer Copay Cards: These are often available for patients with commercial or private insurance to help reduce monthly copayments.
• Patient Assistance Programs: These programs are designed for patients who lack insurance coverage or meet specific low-income criteria, potentially providing the medication at no cost.
• Foundation Support: Independent charitable foundations may offer grants to help cover the cost of cholesterol-lowering medications for patients with specific medical conditions.

Patients are encouraged to speak with their pharmacist or insurance representative to get the most accurate estimate of their costs.